Age-Specific Outcomes of Bioprosthetic vs. Mechanical Aortic Valve Replacement: Balancing Reoperation Risk with Anticoagulation Burden.

IF 2.4 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Fatimah A Alhijab, Latifa A Alfayez, Essam Hassan, Monirah A Albabtain, Ismail M Elnaggar, Khaled A Alotaibi, Adam I Adam, Claudio Pragliola, Huda H Ismail, Amr A Arafat
{"title":"Age-Specific Outcomes of Bioprosthetic vs. Mechanical Aortic Valve Replacement: Balancing Reoperation Risk with Anticoagulation Burden.","authors":"Fatimah A Alhijab, Latifa A Alfayez, Essam Hassan, Monirah A Albabtain, Ismail M Elnaggar, Khaled A Alotaibi, Adam I Adam, Claudio Pragliola, Huda H Ismail, Amr A Arafat","doi":"10.3390/jcdd11070227","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The choice of prosthesis for aortic valve replacement (AVR) remains challenging. The risk of anticoagulation complications vs. the risk of aortic valve reintervention should be weighed. This study compared the outcomes of bioprosthetic vs. mechanical AVR in patients older and younger than 50.</p><p><strong>Methods: </strong>This retrospective study was conducted from 2009 to 2019 and involved 292 adult patients who underwent isolated AVR. The patients were divided according to their age (above 50 years or 50 years and younger) and the type of valves used in each age group. The outcomes of bioprosthetic valves (Groups 1a (>50 years) and 1b (≤50 years)) were compared with those of mechanical valves (Groups 2a (>50 years) and 2b (≤50 years)) in each age group.</p><p><strong>Results: </strong>The groups had nearly equal rates of preexisting comorbidities except for Group 1b, in which the rate of hypertension was greater (32.6% vs. 14.7%; <i>p</i> = 0.025). This group also had higher rates of old stroke (8.7% vs. 0%, <i>p</i> = 0.011) and higher creatinine clearance (127.62 (108.82-150.23) vs. 110.02 (84.87-144.49) mL/min; <i>p</i> = 0.026) than Group 1b. Patients in Group 1a were significantly older than Group 2a (64 (58-71) vs. 58 (54-67) years; <i>p</i> = 0.002). There was no significant difference in the NYHA class between the groups. The preoperative ejection fraction and other echocardiographic parameters did not differ significantly between the groups. Re-exploration for bleeding was more common in patients older than 50 years who underwent mechanical valve replacement (<i>p</i> = 0.021). There was no difference in other postoperative complications between the groups. The groups had no differences in survival, stroke, or bleeding rates. Aortic valve reintervention was significantly greater in patients ≤ 50 years old with bioprosthetic valves. There were no differences between groups in the changes in left ventricular mass, ejection fraction, or peak aortic valve pressure during the 5-year follow-up.</p><p><strong>Conclusions: </strong>The outcomes of mechanical and bioprosthetic valve replacement were comparable in patients older than 50 years. Using bioprosthetic valves in patients younger than 50 years was associated with a greater rate of valve reintervention, with no beneficial effect on the risk of bleeding or stroke.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11277715/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Development and Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jcdd11070227","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The choice of prosthesis for aortic valve replacement (AVR) remains challenging. The risk of anticoagulation complications vs. the risk of aortic valve reintervention should be weighed. This study compared the outcomes of bioprosthetic vs. mechanical AVR in patients older and younger than 50.

Methods: This retrospective study was conducted from 2009 to 2019 and involved 292 adult patients who underwent isolated AVR. The patients were divided according to their age (above 50 years or 50 years and younger) and the type of valves used in each age group. The outcomes of bioprosthetic valves (Groups 1a (>50 years) and 1b (≤50 years)) were compared with those of mechanical valves (Groups 2a (>50 years) and 2b (≤50 years)) in each age group.

Results: The groups had nearly equal rates of preexisting comorbidities except for Group 1b, in which the rate of hypertension was greater (32.6% vs. 14.7%; p = 0.025). This group also had higher rates of old stroke (8.7% vs. 0%, p = 0.011) and higher creatinine clearance (127.62 (108.82-150.23) vs. 110.02 (84.87-144.49) mL/min; p = 0.026) than Group 1b. Patients in Group 1a were significantly older than Group 2a (64 (58-71) vs. 58 (54-67) years; p = 0.002). There was no significant difference in the NYHA class between the groups. The preoperative ejection fraction and other echocardiographic parameters did not differ significantly between the groups. Re-exploration for bleeding was more common in patients older than 50 years who underwent mechanical valve replacement (p = 0.021). There was no difference in other postoperative complications between the groups. The groups had no differences in survival, stroke, or bleeding rates. Aortic valve reintervention was significantly greater in patients ≤ 50 years old with bioprosthetic valves. There were no differences between groups in the changes in left ventricular mass, ejection fraction, or peak aortic valve pressure during the 5-year follow-up.

Conclusions: The outcomes of mechanical and bioprosthetic valve replacement were comparable in patients older than 50 years. Using bioprosthetic valves in patients younger than 50 years was associated with a greater rate of valve reintervention, with no beneficial effect on the risk of bleeding or stroke.

生物人工主动脉瓣置换术与机械主动脉瓣置换术的特定年龄结果:平衡再手术风险与抗凝负担。
背景:主动脉瓣置换术(AVR)假体的选择仍然具有挑战性。应权衡抗凝并发症的风险与主动脉瓣再介入的风险。本研究比较了年龄在 50 岁以上和 50 岁以下的患者接受生物假体和机械主动脉瓣置换术的结果:这项回顾性研究于 2009 年至 2019 年进行,共有 292 名成年患者接受了孤立自体瓣膜置换术。根据患者的年龄(50 岁以上或 50 岁及以下)和每个年龄组使用的瓣膜类型进行了划分。比较了各年龄组生物人工瓣膜(1a组(大于50岁)和1b组(小于50岁))与机械瓣膜(2a组(大于50岁)和2b组(小于50岁))的治疗效果:结果:除1b组患高血压的比例较高外(32.6%对14.7%;P = 0.025),其他各组患原有合并症的比例几乎相同。与 1b 组相比,该组的既往中风率(8.7% 对 0%,p = 0.011)和肌酐清除率(127.62(108.82-150.23)毫升/分钟对 110.02(84.87-144.49)毫升/分钟;p = 0.026)也更高。1a 组患者的年龄明显比 2a 组大(64(58-71)岁 vs 58(54-67)岁;p = 0.002)。两组患者的 NYHA 分级无明显差异。术前射血分数和其他超声心动图参数在两组间无明显差异。接受机械瓣膜置换术的 50 岁以上患者因出血再次手术的比例更高(P = 0.021)。两组患者在其他术后并发症方面没有差异。两组患者的存活率、中风率或出血率均无差异。使用生物人工瓣膜的 50 岁以下患者主动脉瓣再介入率明显更高。在5年随访期间,各组在左心室质量、射血分数或主动脉瓣压力峰值的变化上没有差异:结论:在50岁以上的患者中,机械瓣膜置换术和生物瓣膜置换术的疗效相当。结论:机械瓣膜置换术和生物人工瓣膜置换术对50岁以上患者的疗效相当,而对50岁以下患者使用生物人工瓣膜会导致瓣膜再介入率升高,但对出血或中风风险无益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Cardiovascular Development and Disease
Journal of Cardiovascular Development and Disease CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.60
自引率
12.50%
发文量
381
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信